Ticker Details
Intellia Therapeutics, Inc. Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
IPO Date:	May 6, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.76B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.09 | 3.23%
Avg Daily Range (30 D):	$0.56 | 3.96%
Avg Daily Range (90 D):	$0.50 | 3.68%

Institutional Daily Volume
Avg Daily Volume:	1.39M
Avg Daily Volume (30 D):	6.64M
Avg Daily Volume (90 D):	4.97M

Trade Size
Avg Trade Size (Sh.):	80
Avg Trade Size (Sh.) (30 D):	104
Avg Trade Size (Sh.) (90 D):	97

Institutional Trades
Total Institutional Trades:	5,061
Avg Institutional Trade:	$2.95M
Avg Institutional Trade (30 D):	$3.31M
Avg Institutional Trade (90 D):	$3.1M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.87M
Avg Closing Trade (30 D):	$8.85M
Avg Closing Trade (90 D):	$5.88M
Avg Closing Volume:	172.22K

News

May 6, 2026 @ 2:12 PM Cathie Wood Goes Bargain Hunting: 3 Stocks She Jus... Source: Rick Munarriz

Apr 29, 2026 @ 11:00 AM Intellia Therapeutics Announces Pricing of Public ... Source: Not Specified

Apr 27, 2026 @ 4:09 PM S&P 500 Holds Near Highs Despite Oil Shock and Wea... Source: Itai Smidt

Apr 27, 2026 @ 3:29 PM 3 Biotech Stocks That Could Benefit from the Paten... Source: Chris Markoch

Apr 3, 2026 @ 8:05 PM Intellia Therapeutics Reports Inducement Grants Un... Source: Intellia Therapeutics

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-3.53	$-.81	$-.82
Diluted EPS	$-3.53	$-.81	$-.82
Revenue	$66.09M	$15.05M	$23.02M
Gross Profit
Net Income / Loss	$-394.6M	$-96.23M	$-95.79M
Operating Income / Loss	$-420.72M	$-100.53M	$-98.71M
Cost of Revenue
Net Cash Flow	$-52.69M	$-17.47M	$-39.77M
PE Ratio